GlassScriptPhysician profile
Doron Weiner
NPI 1881751634
$4,960.27
in general payments reported to CMS, 2019-2025
34 companies · $645 in 2025
The $645 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $342 · 2021: $700 · 2022: $731 · 2023: $867 · 2024: $408 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537 · Long Term Medical Supply Or Device Loan: $299 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.06 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,959.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $791.22 | 2019-2025 | Opdivo |
| Incyte Corporation | $311.65 | 2019-2025 | Jakafi |
| Pfizer INC. | $273.32 | 2019-2025 | |
| Astellas Pharma US INC | $165.18 | 2019 | |
| Genentech USA, INC. | $155.20 | 2019-2025 | Tecentriq, Phesgo |
| Alexion Pharmaceuticals, INC. | $123.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $119.11 | 2019-2025 | Keytruda, Keytruda Qlex |
| Menarini Silicon Biosystems, INC. | $98.09 | 2024-2025 | |
| Janssen Biotech, INC. | $85.00 | 2019 | |
| Clovis Oncology, INC. | $75.99 | 2019 | |
| Genzyme Corporation | $68.95 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $68.75 | 2023 | Tazverik |
| Emd Serono, INC. | $67.81 | 2019 | |
| Seagen INC. | $58.05 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $56.74 | 2023-2025 | Vanflyta, Enhertu |
| Abbvie INC. | $53.93 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $52.15 | 2019 | |
| Celgene Corporation | $45.65 | 2019-2022 | |
| Array Biopharma INC | $42.59 | 2019 | |
| Myovant Sciences INC. | $39.13 | 2021 | |
| Glaxosmithkline, LLC. | $24.95 | 2021 | |
| Cti Biopharma Corp. | $24.66 | 2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $22.94 | 2020 | |
| Pharmacosmos Therapeutics INC. | $22.49 | 2025 | Monoferric |
| Organon LLC | $22.01 | 2022 | |
| Eisai INC. | $21.28 | 2019 | |
| Lilly USA, LLC | $21.22 | 2021 | |
| Amag Pharmaceuticals, INC. | $20.00 | 2021 | |
| Aveo Pharmaceuticals, INC. | $17.62 | 2021 | |
| Myriad Genetic Laboratories, INC. | $14.97 | 2024 | Myrisk |
| Blueprint Medicines Corporation | $13.77 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Exelixis INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doron Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.